Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation - 21/07/15
on behalf of the
Consortium for Optimizing the Surgical Treatment of Rectal Cancer (OSTRiCh)
Abstract |
Background |
Many rectal cancer patients experience tumor downstaging and some are found to achieve a pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT). Previous data suggest that there is an association between the time interval from nCRT completion to surgery and tumor response rates, including pCR. However, these studies have been primarily from single institutions with small sample sizes. The aim of this study was to examine the relationship between a longer interval after nCRT and pCR in a nationally representative cohort of rectal cancer patients.
Study Design |
Clinical stage II to III rectal cancer patients undergoing nCRT with a documented surgical resection were selected from the 2006 to 2011 National Cancer Data Base. Multivariable logistic regression analysis was used to assess the association between the nCRT–surgery interval time (<6 weeks, 6 to 8 weeks, >8 weeks) and the odds of pCR. The relationship between nCRT–surgery interval, surgical morbidity, and tumor downstaging was also examined.
Results |
Overall, 17,255 patients met the inclusion criteria. An nCRT–surgery interval time >8 weeks was associated with higher odds of pCR (odds ratio [OR] 1.12, 95% CI 1.01 to 1.25) and tumor downstaging (OR 1.11, 95% CI 1.02 to 1.25). The longer time delay was also associated with lower odds of 30-day readmission (OR 0.82, 95% CI 0.70 to 0.92).
Conclusions |
An nCRT–surgery interval time >8 weeks results in increased odds of pCR, with no evidence of associated increased surgical complications compared with an interval of 6 to 8 weeks. These data support implementation of a lengthened interval after nCRT to optimize the chances of pCR and perhaps add to the possibility of ultimate organ preservation (nonoperative management).
Le texte complet de cet article est disponible en PDF.Abbreviations and Acronyms : NCDB, nCRT, OR, pCR
Plan
| Disclosure Information: Nothing to disclose. |
|
| Disclosures outside the scope of this work: Dr Wexner is a consultant for CareFusion, Edwards LifeSciences, GI View, Incontinence Devices Inc, Johnson & Johnson Medical, Karl Storz Endoscopy-America, Lexington Medical, LifeBond, Mederi Therapeutics, Medtronic, Novadaq, Precision Therapeutics, and Renew Medical. Dr Wexner holds patents and receives royalties from Covidien, Karl Storz Endoscopy-America, novoGI, and Unique Surgical Innovations. Dr Wexner has stock and stock options for Asana Medical, LifeBond, CRH Medical, EZ Surgical, Neatstitch, and novoGI. All other authors have nothing to disclose. |
Vol 221 - N° 2
P. 430-440 - août 2015 Retour au numéro
Article précédent
- Total Occlusive Ionic Silver-Containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection
- Jaime Ruiz-Tovar, Carolina Llavero, Vicente Morales, Carlos Gamallo
- Using Merged Clinical and Claims Registry Data to Identify High Utilizers of Surgical Inpatient Care 1 Year after Colectomy
- Anne M. Stey, Marcia M. Russell, David S. Zingmond, Melinda M. Gibbons, Bruce L. Hall, Jack Needleman, Elise H. Lawson, Nancy Liu, Clifford Y. Ko
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?